QualityStocks

[QualityStocks]

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Sees New Round of Investors Attracted to Cannabis Market

- Has patents in the United States and Australia and patents pending in more than 40 countries for proprietary technology easing how edible cannabinoids enter body

- Revenue stream comes from own products and 5-10% margin of gross sales from licensing technology to third parties

- Signed C$250,000 joint venture agreement with National Research Council (NRC) in Canada to research and find best methods for processing active agents in foods


Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) already owns international patents for its proprietary intellectual property and has more global patents pending in the cannabis marketplace. It believes that the sub-sector of bioscience technology for edible CBDs will expand. It expects a new round of investors will be attracted to “plant-to-bloodstream” companies. Initially, it said, investors funded “seed-to-plant” companies.

The Kelowna, British Columbia, Canada-based food bioscience company is a technology disruptor for edible CBDs. It markets a high absorption hemp oil formula, protein energy bars, exotic teas and high absorption hemp oil capsules to help the human body absorb CBDs. In its June 2017 corporate presentation for investors (http://dtn.fm/3v1NR), Lexaria Bioscience noted that its focus is on researching and developing additional products for the edible cannabinoids market. It owns international patent rights and has pending patents for its technology changing the way cannabinoids enter the body.

This sub-sector is in its relative infancy as companies seeks to learn more about the medicinal potential for medical marijuana. Lexaria Bioscience is the only publicly traded company which has intellectual property in this sub-sector, covering non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and vitamins, according to a July 2017 market research report titled, “Biotech Players Lead the Growth Charge in the Legal Cannabis Market” (http://dtn.fm/ojRn1). The company has received for its proprietary technology its first patents in the United States and Australia and has patents pending in more than 40 countries globally.

Lexaria’s technology aims to improve the human body’s absorption of CBDs in the gastrointestinal tract. The process is effective, not just for CBDs, but also for other non-psychoactive cannabinoids. Patents are pending, too, for NSAIDs, nicotine and other molecules, per the research report.

By masking the bitter taste, reducing ingestion time and improving bio-absorption of CBD products, Lexaria Bioscience enjoys revenue streams from its own product line brands, such as Turbo CBD™, ViPova™, and Lexaria Energy Foods, as well as from licensing to third party partners at a 5-10% margin of gross sales.

Lexaria Bioscience has also just signed a C$250,000 collaborative research agreement with the National Research Council (NRC) of Canada for an 18-month term to investigate opportunities to evaluate and determine the best methods for processing lipophilic active agents within foods. The research will also study cannabinoids such as THC, vitamins, nicotine and NSAIDs. The result could be isolating a chemical or physical “fingerprint” identification to study Lexaria’s technology in consumer products, the company’s investor presentation said.

For more information, visit the company’s website at www.LexariaEnergy.com